000288566 001__ 288566
000288566 005__ 20260220120849.0
000288566 0247_ $$2doi$$a10.3390/jcm13040957
000288566 0247_ $$2pmid$$apmid:38398270
000288566 0247_ $$2pmc$$apmc:PMC10889253
000288566 037__ $$aDKFZ-2024-00412
000288566 041__ $$aEnglish
000288566 082__ $$a610
000288566 1001_ $$0P:(DE-He78)c7f6680647a8e992f04c9e075784f775$$aWeykamp, Fabian$$b0$$eFirst author$$udkfz
000288566 245__ $$aDaily AI-Based Treatment Adaptation under Weekly Offline MR Guidance in Chemoradiotherapy for Cervical Cancer 1: The AIM-C1 Trial.
000288566 260__ $$aBasel$$bMDPI$$c2024
000288566 3367_ $$2DRIVER$$aarticle
000288566 3367_ $$2DataCite$$aOutput Types/Journal article
000288566 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1708935697_12922
000288566 3367_ $$2BibTeX$$aARTICLE
000288566 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000288566 3367_ $$00$$2EndNote$$aJournal Article
000288566 500__ $$a#EA:E050#LA:E050#
000288566 520__ $$a(1) Background: External beam radiotherapy (EBRT) and concurrent chemotherapy, followed by brachytherapy (BT), offer a standard of care for patients with locally advanced cervical carcinoma. Conventionally, large safety margins are required to compensate for organ movement, potentially increasing toxicity. Lately, daily high-quality cone beam CT (CBCT)-guided adaptive radiotherapy, aided by artificial intelligence (AI), became clinically available. Thus, online treatment plans can be adapted to the current position of the tumor and the adjacent organs at risk (OAR), while the patient is lying on the treatment couch. We sought to evaluate the potential of this new technology, including a weekly shuttle-based 3T-MRI scan in various treatment positions for tumor evaluation and for decreasing treatment-related side effects. (2) Methods: This is a prospective one-armed phase-II trial consisting of 40 patients with cervical carcinoma (FIGO IB-IIIC1) with an age ≥ 18 years and a Karnofsky performance score ≥ 70%. EBRT (45-50.4 Gy in 25-28 fractions with 55.0-58.8 Gy simultaneous integrated boosts to lymph node metastases) will be accompanied by weekly shuttle-based MRIs. Concurrent platinum-based chemotherapy will be given, followed by 28 Gy of BT (four fractions). The primary endpoint will be the occurrence of overall early bowel and bladder toxicity CTCAE grade 2 or higher (CTCAE v5.0). Secondary outcomes include clinical feasibility, quality of life, and imaging-based response assessment.
000288566 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000288566 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000288566 650_7 $$2Other$$aMR guidance
000288566 650_7 $$2Other$$acervical cancer
000288566 650_7 $$2Other$$achemoradiotherapy
000288566 650_7 $$2Other$$aonline adaptive radiotherapy
000288566 7001_ $$00000-0001-7087-9581$$aMeixner, Eva$$b1
000288566 7001_ $$00000-0002-2389-5404$$aArians, Nathalie$$b2
000288566 7001_ $$0P:(DE-HGF)0$$aHoegen-Saßmannshausen, Philipp$$b3
000288566 7001_ $$aKim, Ji-Young$$b4
000288566 7001_ $$0P:(DE-He78)4f5721350bd23340e626cb0340bef47a$$aTawk, Bouchra$$b5$$udkfz
000288566 7001_ $$0P:(DE-He78)34ad9f967b71b1438cf5490a115c02d2$$aKnoll, Maximilian$$b6$$udkfz
000288566 7001_ $$0P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aHuber, Peter$$b7$$udkfz
000288566 7001_ $$aKönig, Laila$$b8
000288566 7001_ $$aSander, Anja$$b9
000288566 7001_ $$0P:(DE-He78)bb99ed05244bff1747c47fc8a34c1795$$aMokry, Theresa$$b10$$udkfz
000288566 7001_ $$0P:(DE-He78)d64d0859db43c1fe655c24f191755d94$$aMeinzer, Clara$$b11$$udkfz
000288566 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b12$$udkfz
000288566 7001_ $$0P:(DE-He78)440a3f62ea9ea5c63375308976fc4c44$$aJäkel, Oliver$$b13$$udkfz
000288566 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b14$$udkfz
000288566 7001_ $$0P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aHörner-Rieber, Juliane$$b15$$eLast author$$udkfz
000288566 773__ $$0PERI:(DE-600)2662592-1$$a10.3390/jcm13040957$$gVol. 13, no. 4, p. 957 -$$n4$$p957$$tJournal of Clinical Medicine$$v13$$x2077-0383$$y2024
000288566 8564_ $$uhttps://inrepo02.dkfz.de/record/288566/files/jcm-13-00957.pdf$$yOpenAccess
000288566 8564_ $$uhttps://inrepo02.dkfz.de/record/288566/files/jcm-13-00957.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000288566 909CO $$ooai:inrepo02.dkfz.de:288566$$popenaire$$pdnbdelivery$$pdriver$$pVDB$$popen_access
000288566 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c7f6680647a8e992f04c9e075784f775$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000288566 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000288566 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4f5721350bd23340e626cb0340bef47a$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000288566 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)34ad9f967b71b1438cf5490a115c02d2$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000288566 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000288566 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb99ed05244bff1747c47fc8a34c1795$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000288566 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d64d0859db43c1fe655c24f191755d94$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000288566 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000288566 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)440a3f62ea9ea5c63375308976fc4c44$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000288566 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000288566 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000288566 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000288566 9141_ $$y2024
000288566 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000288566 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-04-12T14:59:21Z
000288566 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
000288566 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN MED : 2022$$d2023-08-25
000288566 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000288566 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T14:59:21Z
000288566 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T14:59:21Z
000288566 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000288566 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-25
000288566 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000288566 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000288566 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000288566 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
000288566 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-25
000288566 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-25
000288566 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000288566 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
000288566 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000288566 9202_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000288566 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000288566 9201_ $$0I:(DE-He78)E210-20160331$$kE210$$lE210 KKE Translationale Radioonkologie$$x1
000288566 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x2
000288566 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x3
000288566 9201_ $$0I:(DE-He78)E040-20160331$$kE040$$lE040 Med. Physik in der Strahlentherapie$$x4
000288566 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x5
000288566 9200_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000288566 980__ $$ajournal
000288566 980__ $$aVDB
000288566 980__ $$aUNRESTRICTED
000288566 980__ $$aI:(DE-He78)E050-20160331
000288566 980__ $$aI:(DE-He78)E210-20160331
000288566 980__ $$aI:(DE-He78)E055-20160331
000288566 980__ $$aI:(DE-He78)E010-20160331
000288566 980__ $$aI:(DE-He78)E040-20160331
000288566 980__ $$aI:(DE-He78)HD01-20160331
000288566 9801_ $$aFullTexts